摘要
目的探讨磺达肝癸钠与依诺肝素治疗不稳定型心绞痛并糖尿病患者的疗效及对凝血功能指标的影响。方法300例不稳定型心绞痛并糖尿病患者,随机分为对照组和观察组,每组150例。两组患者均行常规治疗,在此基础上,对照组采用依诺肝素治疗,观察组患者采用磺达肝癸钠治疗。比较两组患者治疗前后凝血功能指标[活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)、D-二聚体(D-D)及血小板(PLT)]、血糖指标(空腹血糖、餐后2 h血糖)及心血管不良事件发生率、出血发生率。结果观察组患者治疗前APTT、TT、FIB、D-D及PLT分别为(31.34±3.09)s、(12.25±1.50)s、(3.52±0.39)g/L、(2.37±0.31)mg/L、(228.39±9.23)×10^(9)/L,治疗后分别为(32.17±2.99)s、(13.14±1.23)s、(2.39±0.22)g/L、(0.66±0.12)mg/L、(208.19±7.34)×10^(9)/L;对照组患者治疗前APTT、TT、FIB、D-D及PLT分别为(31.50±2.18)s、(12.27±1.52)s、(3.54±0.42)g/L、(2.36±0.35)mg/L、(229.03±9.54)×10^(9)/L,治疗后分别为(32.08±1.58)s、(13.17±1.19)s、(2.43±0.25)g/L、(0.68±0.14)mg/L、(209.44±6.68)×10^(9)/L。治疗前后,两组患者APTT、TT、FIB、D-D及PLT组间比较差异均无统计学意义(P>0.05);治疗后,两组患者APTT、TT均长于本组治疗前,FIB、D-D、PLT水平均低于本组治疗前,差异具有统计学意义(P<0.05)。观察组患者治疗前空腹血糖、餐后2 h血糖水平分别为(9.35±1.38)、(10.89±1.25)mmol/L,治疗后分别为(6.05±0.93)、(7.79±1.39)mmol/L;对照组患者治疗前空腹血糖、餐后2 h血糖水平分别为(9.39±1.40)、(10.92±1.28)mmol/L,治疗后分别为(6.14±0.88)、(7.69±1.44)mmol/L。治疗前后,两组患者空腹血糖、餐后2 h血糖水平组间比较差异均无统计学意义(P>0.05);治疗后,两组患者空腹血糖、餐后2 h血糖水平均低于本组治疗前,差异具有统计学意义(P<0.05)。两组患者心血管事件发生率比较差异无统计学意义(P>0.05);观察组患�
Objective To discuss the efficacy of fondaparinux sodium and enoxaparin on patients with unstable angina pectoris and diabetes mellitus and its impact on coagulation function indexes.Methods A total of 300 patients with unstable angina pectoris and diabetes mellitus were randomly divided into a control group and an observation group,with 150 patients in each group.Patients in both groups were treated conventionally,and on this basis,the control group was treated with enoxaparin and the observation group was treated with fondaparinux sodium.Both groups were compared in terms of coagulation indexes[activated partial thromboplastin time(APTT),prothrombin time(TT),fibrinogen(FIB),D-dimer(D-D)and platelet(PLT)],blood glucose index(fasting blood glucose,2 h postprandial blood glucose)before and after treatment,and the incidence of cardiovascular adverse events and bleeding.Results In the observation group,the APTT,TT,FIB,D-D and PLT were(31.34±3.09)s,(12.25±1.50)s,(3.52±0.39)g/L,(2.37±0.31)mg/L and(228.39±9.23)×10^(9)/L before treatment,and(32.17±2.99)s,(13.14±1.23)s,(2.39±0.22)g/L,(0.66±0.12)mg/L and(208.19±7.34)×10^(9)/L after treatment.In the control group,the APTT,TT,FIB,D-D and PLT were(31.50±2.18)s,(12.27±1.52)s,(3.54±0.42)g/L,(2.36±0.35)mg/L and(229.03±9.54)×10^(9)/L before treatment,and(32.08±1.58)s,(13.17±1.19)s,(2.43±0.25)g/L,(0.68±0.14)mg/L and(209.44±6.68)×10^(9)/L after treatment.Before and after treatment,there were no statistically significant differences in APTT,TT,FIB,D-D and PLT between the two groups(P>0.05).After treatment,the APTT and TT of patients in both groups were longer than those before treatment in this group,and the levels of FIB,D-D and PLT were lower than those before treatment in this group.The differences were statistically significant(P<0.05).In the observation group,the fasting blood glucose and 2 h postprandial blood glucose levels were(9.35±1.38)and(10.89±1.25)mmol/L before treatment,and(6.05±0.93)and(7.79±1.39)mmol/L after treatment.In the control group
作者
孙洪伟
SUN Hong-wei(Department of Cardiology,Hefei BOE Hospital,Hefei 230000,China)
出处
《中国实用医药》
2023年第8期108-111,共4页
China Practical Medicine
关键词
磺达肝癸钠
依诺肝素
不稳定型心绞痛
糖尿病
凝血功能
Fondaparinux sodium
Enoxaparin
Unstable angina pectoris
Diabetes mellitus
Coagulation function
